Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Dana-Farber Cancer Institute, Inc. v. Bristol-Myers Squibb Co. et al
Case Number:
1:19-cv-11380
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
April 06, 2023
Bristol-Myers, Dana-Farber Settle Cancer IP Dispute
Bristol-Myers Squibb Co. and the Dana-Farber Cancer Institute have resolved a dispute in Massachusetts federal court over licensing revenue for six groundbreaking immunology patents, according to a Thursday court filing.
-
January 25, 2023
Bristol-Myers Gets Pushback On Early Win Bid Over Cancer IP
Bristol-Myers Squibb Co. faced headwinds in Boston federal court Wednesday in arguing for a pretrial win in a lawsuit claiming it robbed Dana-Farber Cancer Institute of licensing revenue from groundbreaking immunology patents the research center now co-owns.
-
August 01, 2022
Bristol-Myers Says Its Former Lawyer Can't Testify In IP Battle
Bristol-Myers Squibb Co. told a federal judge that Dana-Farber Cancer Institute should not be allowed to bring in a former BMS patent attorney from McDonnell Boehnen Hulbert & Berghoff LLP to testify against his onetime client as part of an ongoing dispute over immunology patents.
-
August 16, 2021
Judge Lets Dana-Farber Advance Cancer Drug IP Suit
A Massachusetts federal judge has found that the Dana-Farber Cancer Institute made a plausible argument asserting that it is entitled to damages after Bristol-Myers Squibb left the research center's name off immunology patents.
-
April 26, 2021
Pfizer 'Bonus' Irks Judge In Bristol-Myers Cancer IP Dispute
A Massachusetts federal judge on Monday grilled Bristol-Myers Squibb Co. and Dana-Farber Cancer Institute over "troubling" settlement terms related to their prior high-profile patent ownership case that appeared to offer a bonus to intervenor Pfizer Inc. if the Boston nonprofit cancer hospital lost the case.
-
June 24, 2019
Cancer Center Claims Drug Cos. 'Robbed' It Of IP Revenue
Boston-based Dana-Farber Cancer Institute says it should get a cut of more than $1.6 billion in licensing revenue Bristol-Myers Squibb Co. and Ono Pharmaceutical Co. Ltd. have raked in from immunology patents the institute says it co-owns, according to a new lawsuit.